Onconetix subsidiary amends Labcorp license; up to $300k for PRIME study of Proclarix

Onconetix, Inc.

Proteomedix (wholly owned by Onconetix) amended license with Labcorp for a new validation study of Proclarix (PRIME Study).
Onconetix will pay Labcorp milestone-based payments up to $300,000 total and bear all study costs.
Mid-five-figure payments per enrolled subject batch; fixed per-subject fee if final milestone not met.
Labcorp not required to pay royalties or milestones for use of the risk calculator in this PRIME Study.
Labcorp must provide study results to Onconetix but Onconetix cannot use or disclose without Labcorp's consent.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Onconetix, Inc. amended Amendment with Laboratory Corporation of America Holdings (Labcorp) (effective 2025-12-06).

Action: amendment
Agreement: license
Counterparty: Laboratory Corporation of America Holdings (Labcorp)
Effective: 2025-12-06

Exact text from the filing

On December 6, 2025, Proteomedix AG, a Swiss Company (“Proteomedix”), a wholly-owned subsiairy of Onconetix, Inc. (the “Company”), entered into an amendment (the “Amendment”) of the license agreement with Laboratory Corporation of America Holdings (“Labcorp”) dated as of March 27, 2023, by and between the Company and Labcorp (the “Agreement”), pursuant to which Labcorp has the exclusive right to develop and commercialize Proclarix and other products developed by Labcorp using Proteomedix’s intellectual property covered by the license in the United States (the “Licensed Products”).

View on SEC.gov

269 material agreements filed in the last 30 days. Browse all material agreements →

Onconetix, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-119898

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.